Methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis (CF) impairs lung function and contributes to the progression of the disease. Optimal eradication regimens for new-onset MRSA infections in people with CF (pwCF) remain undefined.
Materials and Methods:
This prospective, multicenter study evaluated a standardized, step-up MRSA eradication regimen in pwCF with new-onset MRSA infections between 2020 and 2022.
Results:
Ninety-one pwCF (52.7% male, median age: 9 years) were included. Our treatment regimen included oral rifampicin and co-trimoxazole or oral rifampicin and fusidic acid. Intravenous teicoplanin treatment was initiated in patients whose clinical condition was unstable. The eradication success rates after 1 year were 82.4%, 92.9%, and 55.6%, respectively. No significant changes in median FEV1% predicted or BMI z-scores were observed between MRSA-eradicated and non-eradicated groups at baseline or 12 months.
Conclusion:
A standardized step-up MRSA eradication protocol is effective for new-onset MRSA infections in pwCF. Randomized controlled trials are needed to confirm these findings.
TerlizziVBalleriniTCastaldoA, et al. Clinical features and outcomes of persons with cystic fibrosis and nocardia isolation: a systematic review. BMC Pulm Med. 2024;24:440.
2.
BlanchardACWatersVJ.Microbiology of cystic fibrosis airway disease. Semin Respir Crit Care Med. 2019;40(6):727-736.
3.
TurciosNL.Cystic fibrosis lung disease: an overview. Respir Care. 2020;65(2):233-251.
4.
DasenbrookECMerloCADiener-WestM, et al. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(8):814-821.
RogersGBTaylorSLHoffmanLRBurrLD.The impact of CFTR modulator therapies on CF airway microbiology. J Cyst Fibros. 2020;19(3):359-364.
7.
TerlizziVFarrellPM.Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians. Curr Probl Pediatr Adolesc Health Care. 2024;54(6):101637.
8.
MuhlebachMS.Methicillin-resistant Staphylococcus aureus in cystic fibrosis: how should it be managed?Curr Opin Pulm Med. 2017;23(6):544-550.
9.
AkilNMuhlebachMS.Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis. Pediatr Pulmonol. 2018;53(S3):S64-S74.
10.
CastellaniCDuffAJABellSC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153-178.
11.
MogayzelPJNaureckasETJrRobinsonKA, et al. Cystic fibrosis foundation pulmonary guideline pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11(10):1640-1650.
12.
CoxDWKellyCRushRO’SullivanNCannyGLinnaneB.The impact of MRSA infection in the airways of children with cystic fibrosis; a case-control study. Ir Med J. 2011;104(10):305-308.
13.
SawickiGSRasouliyanLPastaDJ, et al. Impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol. 2008;43(11):1117-1123.
14.
VanderhelstEDe MeirleirLVerbanckS, et al. Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients. J Cyst Fibros. 2012;11(1):2-7.
15.
DasenbrookECCheckleyWMerloCA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010;303(23):2386-2392.
16.
RenCLMorganWJKonstanMW, et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol. 2007;42(6):513-518.
17.
SandersDBBittnerRCRosenfeldM, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182(5):627-632.
18.
Brompton HarefieldR; NHS Foundation Trust.Clinical Guidelines: Care of Children With Cystic Fibrosis. 7th ed.London: Royal Brompton Hospital; 2017.
19.
VanderhelstEDe WachterEWillekensJPiérardDVinckenWMalfrootA.Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of 11 patients. J Cyst Fibros. 2013;12(6):662-666.
20.
MacfarlaneMLeavyAMcCaughanJFairRReidAJ.Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect. 2007;65(3):231-236.
21.
HallHGadhokRAlshafiKBiltonDSimmondsNJ.Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre. Respir Med. 2015;109(3):357-363.
22.
SerisierDJJonesGCarrollM.Eradication of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis with linezolid. J Cyst Fibros. 2004;3(1):61.
23.
LoDKMuhlebachMSSmythAR.Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev. 2022;12(12):CD009650.
24.
MursalogluHHAkınCYılmaz YeğitC, et al. Comparison of intravenous and non-intravenous antibiotic regimens in eradication of P. aeruginosa and MRSA in cystic fibrosis. Pediatr Pulmonol. 2021;56(12):3745-3751.
25.
KapplerMNagelFFeilckeM, et al. Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: a single center observational study. Pediatr Pulmonol. 2016;51(10):1010-1019. doi:10.1002/ppul.23519.
26.
FarrellPMWhiteTBRenCL, et al. Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation. J Pediatr. 2017;181S:S4-S15.
27.
LeeTWBrownleeKGConwaySPDentonMLittlewoodJM.Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34.
28.
FuchsHJBorowitzDSChristiansenDH, et al. Effect of aerosolized recombinant human Dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. N Engl J Med. 1994;331(10):637.
29.
DezubeRJenningsMTRykielM, et al. Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J Cyst Fibros. 2019;18(3):357-363.
30.
DolceDNeriSGrisottoL, et al. Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: a randomized multicenter study. PLoS ONE. 2019;14(3):e0213497.
31.
MuhlebachMSBeckettVPopowitchE, et al. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomized controlled trial. Thorax. 2017;72(4):318-326.
32.
BelarskiEPettitR.Outcomes of a methicillin-resistant Staphylococcus aureus (MRSA) eradication protocol in pediatric cystic fibrosis (CF) patients. Pediatr Pulmonol. 2020;55(3):654-659.
33.
HewerSCLSmythARBrownM, et al. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO- CF): a randomised controlled trial. Lancet Respir Med. 2020;8(10):975-986.
34.
GarskeLAKiddTJGanR, et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect. 2004;56(3):208-214.
35.
DoeSJMcSorleyAIsalskaB, et al. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros. 2010;9(2):104-109.
36.
JenningsMTDasenbrookECLechtzinNBoyleMPMerloCA.Risk factors for persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J Cyst Fibros. 2017;16(6):681-686.
